Valvular Complications Related to Microaxial Assist Device Use: A Case‐Level Systematic Review
Artificial Organs · 2025
DOI: 10.1111/aor.70056 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Artificial Organs, 2025. Verfasst von George P Nolan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, Aortic Valve Insufficiency, Mitral Valve Insufficiency. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
Microaxial devices provide effective short‐term hemodynamic support in patients with cardiogenic shock or during high‐risk procedures. However, there is a paucity of data regarding device‐associated valvular complications. We sought to pool existing data to understand its incidence, management, and outcomes.
Methods
An electronic search was conducted in October 2024 to identify studies reporting microaxial device–associated valvular complications that did not resolve with device explantation. A total of 26 case reports and case series, representing 27 patients, were included. Patient‐level data were extracted for analysis.
Results
The median age was 50 years [IQR 34–65], and 78% (21/27) were male. The indications for microaxial support were cardiogenic shock (85.2%, 23/27), coronary bypass grafting (7.4%, 2/27), and high‐risk percutaneous coronary intervention (7.4%, 2/27). The most commonly used devices were the Impella 5.0 (41%, 11/27) and Impella CP (22%, 6/27). Aortic regurgitation (AR) developed in 67% of patients (18/27). Mitral regurgitation (MR) developed in 33% (9/27) of patients, all of which were severe. The median duration of microaxial support was 10 [3–15] days. Overall, 74% (20/27) of patients underwent surgical management, 11% (3/27) underwent transcatheter treatment, and 15% (4/27) were managed nonoperatively. In‐hospital/30‐day mortality was 11% (3/27), including two deaths among patients with MR (22%) and one in a patient with AR (5.6%) with a pre‐existing bioprosthetic aortic valve ( p = 0.19). When considering the patients with only native valves and excluding the bioprosthetic aortic valve, mortality was significantly higher among MR patients compared to those with AR (MR: 22%; AR: 0%, p = 0.04). At a median follow‐up of 183 [30–365] days, overall survival was 89% (24/27).
Conclusion
AR was more common than MR; however, all MR cases were severe. MR may be associated with worse outcomes. Surgical management appears to be the most frequently employed strategy for valvular injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
- Department of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- The Lawrenceville School, Lawrenceville, New Jersey, USA.
ORCID-Profile: Daler Rahimov, T Reese Macmillan
Zitieren
APA
Nolan, G. P., Hammond, M. C., Rahimov, D., Karimanasseri, C., Nasher, N., Macmillan, T. R., Entwistle, J. W., Rajagopal, K., Hoopes, C. W., & Tchantchaleishvili, V. (2025). Valvular Complications Related to Microaxial Assist Device Use: A Case‐Level Systematic Review. Artificial Organs. https://doi.org/10.1111/aor.70056
Vancouver
Nolan GP, Hammond MC, Rahimov D, Karimanasseri C, Nasher N, Macmillan TR, et al. Valvular Complications Related to Microaxial Assist Device Use: A Case‐Level Systematic Review. Artificial Organs. 2025. doi:10.1111/aor.70056
BibTeX
@article{Nolan2025,
author = {Nolan, George P and Hammond, Magdalena C and Rahimov, Daler and Karimanasseri, Chaitanya and Nasher, Nayeem and Macmillan, T Reese and Entwistle, John W and Rajagopal, Keshava and Hoopes, Charles W and Tchantchaleishvili, Vakhtang},
title = {Valvular Complications Related to Microaxial Assist Device Use: A Case‐Level Systematic Review},
journal = {Artificial Organs},
year = {2025},
doi = {10.1111/aor.70056}
}
EUVIMED